Arrhythmia Monitoring Devices Market Share

Global Arrhythmia Monitoring Devices Market Overview

As per the analysis conducted by Market Research Future (MRFR), the arhythmia monitoring devices market size was valued at USD 4.30 Billion in 2023. The Global Arrhythmia Monitoring Devices industry is projected to grow from USD 5.60 Billion in 2024 to USD 8.20 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.32% during the forecast period (2024 - 2032). A cardiac arrhythmia is a condition where the heartbeat is irregular, i.e., either too slow or too fast. The state is also known as cardiac dysrhythmia.

The growing usage of telecardiology and the on-going development of smart cardiac monitors are expected to be a significant factor that can grow the global market of arrhythmia monitoring devices. In addition, the portability of cardiac arrhythmia monitoring devices is predicted to increase its demand that can augment the market size.

On the flip side, expenses associated with remote cardiac arrhythmia monitoring and product recalls are projected to hinder the market growth of the arrhythmia monitoring devices during the review timeframe.

COVID-19 has adversely impacted the arrhythmia monitoring devices market due to the disruption in the supply chain. Besides, the supply chain, the production process has also been affected severely. In addition, the imposition of lockdown in various lucrative markets, such as India, Italy, and others, is expected to derail the market momentum further.

In January 2022, the US FDA approved Biotricity’s Biotres Cardiac Monitoring Device for arrhythmia monitoring and ECG through a 510(k) clearance. It is a wearable Holter Patch known as a Biotres Cardiac Monitoring Device that records continuously in three channels of ECG data. This has enabled the company to diversify its lineup of cellular devices in the United States.

Cardiologs began using Holter recordings more often than ECGs in June 2022 to detect more atrial fibrillation cases. The French company carried out extensive research on the Holter recordings, which demonstrated that this algorithm would be capable of determining the absence or existence of AFib symptoms within the initial twenty-four hours.

In June 2022, Medicalgorithms received an FDA grant for its Qpatch wearable devices to accurately measure electrocardiograms in various ways. For instance, the interaction between these wearable devices can be indicated by the e-link screen attached to Qpatch. Additionally, it is possible to see real-time readings from this instrument by doing quality control on presently recorded ECG signals.

The release was made by Apple for WatchOS9, which allowed highly precise detection and analysis of symptoms of AFib (atrial fibrillation) & medication monitoring during its launching time. Oura & Fitbit are among Apple’s direct rivals that have been caught up with through such a product; besides, it embraced Apple's cardiac monitoring technology, too.

Medtronic announced in April 2022 that it will introduce AccuRhythm AI – an efficient AI algorithm for heart rate monitoring across Europe. This algorithm effectively applies AI technology to the cardiac rhythm event data collected by LiNQ II. Thus, surgeons get very reliable information; they therefore treat any abnormal cardiac rhythms without worrying about making mistakes. In May 2021, iRhythm Technologies Inc., a leading digital healthcare solutions company focused on advancing cardiac care, received two new 510(k) clearances: one for an entirely new Zio monitor design, “new Zio monitor” and the second one for updated AI capabilities.

In November 2021, Philips agreed to buy Cardiologs, a medical technology company based in France that focuses on cardiac diagnostics through AI and Cloud. Through this purchase, Philips will have enhanced software technology solutions for its ECG analysis electrocardiogram reporting services.

In February 2021, RhythMedix introduced their next-generation wearable novel cardiac telemetry monitor that contains built-in 4G cellular connectivity for arrhythmia detection. This could pave the way for the growth of more similar types of portable and mobile cardiac monitors, thus advancing the market.

BIOMONITOR III is a novel injectable cardiac monitor from Biotronik launched in January 2020 capable of detecting abnormal heart rhythms. New product launches coupled with technological improvements are expected to enhance growth prospects at the company.

Arrhythmia Monitoring Devices Market Trends

Arrhythmia monitoring system has been gaining significance in recent years owing to the rising cases of heart diseases. The ease of FDA approvals, increasing adoption of low-cost electrocardiogram (ECG) devices, and the increasing geriatric population are some salient causes that can propel the industry in the coming period. In addition, the mounting cases of cardiac disorders are likely to favor market expansion in the assessment period.

 However, complications related to these devices may negatively affect the expansion of the arrhythmia monitoring devices market over the assessment period.

Drivers

Innovation in Product to Grow the Adoption of Device among Professionals

The on-going technical development allowing remote monitoring of cardiac rhythm in patients is expected to be one of the most salient factors that can augment the market in the coming period.  The high accuracy and efficiency provided by arrhythmia detection is expected to surge its demand, thereby raising the market. Furthermore, the growing requirement for continuous cardiac rhythm monitoring in the emergency department is expected to augment the arrhythmia monitoring devices market size in the assessment period.

Opportunities

Growing Incidence of CVDs to Offer Market Expansion Opportunities

Adoption of unhealthy diet such as; consumption of a sugar-rich diet, smoking, alcoholism, and higher adoption of a sedentary lifestyle are some of the crucial factors that can offer various expansion opportunities to the arrhythmia monitoring devices industry.

Restraints

Associated Complications can impede the market

Despite the propelling factors, the market can witness hindrance in the coming period. The complications related to such devices along with the rise in recalls of arrhythmia monitoring devices can bring negative impact on the arrhythmia monitoring devices market share.

Challenges

Lack of Resources can pose a Severe Challenge to Grow the Market

The market is predicted to experience a challenge due to the lack of expertise. In addition, some cardiac monitoring devices may have a negative impact on patients, which is another potent challenge that can restrict the market from growing.

Cumulative Growth Analysis

The market is projected to Show Steady Growth in the Assessment Timeframe

The market for arrhythmia monitoring devices is expected to experience a notable expansion in the coming period owing to the increasing cases of CVDs along with the expansion of geriatric population.

Arrhythmia Monitoring Devices Market Segment Insights

Arrhythmia Monitoring Devices Device Type Insights

Holter Monitor Expected to Gain Prominence

Based on type, the global market for cardiac arrhythmia monitoring devices is segmented into event monitor, resting ECG, implantable cardiac monitor (ICM), mobile cardiac telemetry (MCT) devices, Holter monitor, and others. Holter monitor is predicted to gain prominence in the coming period due to the introduction of wireless wearable technology in the device.

Arrhythmia Monitoring Devices Application Insights

The Tachycardia Segment to Grow Significantly

Based on application, the global market for arrhythmia monitoring devices market is segmented into bradycardia, tachycardia, atrial fibrillation (A-fib), premature ventricular contractions (PVC), ventricular fibrillation (V-fib), conduction disorders, and others. Among all, the tachycardia segment is expected to grow significantly during the forecast period.

Arrhythmia Monitoring Devices End-User Insights

Hospitals and Clinics to Dominate the Market

Based on type, the global market for arrhythmia monitoring devices market is segmented into ambulatory surgery centers (ASC), diagnostic centers, hospitals & clinics, home care settings, and others. The hospitals and clinics segment accounted for a market value of USD 1,740.0 Million in 2018.

Arrhythmia Monitoring Devices Regional Insights

North America is expected to dominate the Cardiac Arrhythmic Monitoring Devices Market

North America is estimated to dominate the arrhythmia monitoring devices market growth during the assessment period. The growing awareness created by several initiatives taken by governments and as well as private firms are likely to play a salient role in underpinning the market expansion. The rising collaborations between research labs and institutions is propelling the market growth of the arrhythmia monitoring devices in the region.

The European arrhythmia monitoring devices market is expected to be the second-largest market owing to the growing occurrences of cardiac disorders in the region. In Europe, Spain accounted for a market share of 5.5% in 2018.

Asia-Pacific is estimated to be the fastest-growing market owing to the developing healthcare infrastructure and increasing disposable income. The increasing geriatric population and the rising integration of the latest technologies are expected to drive the regional market. In addition, the availability of portable and home-based arrhythmia monitors are projected to play a salient role in developing the regional market in the coming period.

The Middle East and Africa is projected to experience steady expansion owing to the limited access and healthcare affordability among the population. However, the market can show significant growth due to the presence of untapped market opportunities.

Competitive Landscape

Better Distribution System to Fuel the Competition

The market leaders with sufficient funds can afford a better distribution system and efficient funds for research that is anticipated to strengthen the prevailing competition among the established key players. In addition, the emergence of small players owing to the growing awareness is expected to enhance the competitiveness of the trade further.

Industry News

November 2020: The San Francisco-based company Fitbit received approval from the US Food and Drug Administration (FDA) for its electrocardiogram (ECG) app to assess heart rhythm for atrial fibrillation.

Key Players

• Abbott Laboratories (US)


• BioTelemetry Inc. (US)


• Fukuda Denshi Co. Ltd (Japan)


• Applied Cardiac Systems Inc. (US)


• Medtronic plc (Ireland)


• Nihon Kohden Corporation (Japan)


• Alive Cor Inc. (US)


• Biotronik (Germany)


• GE Healthcare (US)


• Spacelabs Healthcare (US)

Report Overview

Arrhythmia Monitoring Devices Market is predicted to show significant growth in the assessment period. The market is projected to augment due to the on-going technical development in the market along with the growing awareness about the CVDs.